Vectors Research Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Vectors Research Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-7,000	Closed	-$12K	–	140
2022 Q2	$12K	Buy	+7,000	New	+$12K	﹤0.01%	329
2022 Q1	–	Sell	-7,000	Closed	-$26K	–	463
2021 Q4	$26K	Buy	7,000 +1,000	+17%	+$4.55K	0.01%	311
2021 Q3	$31K	Buy	6,000 +2,000	+50%	+$8.97K	0.01%	271
2021 Q2	$17K	Buy	+4,000	New	+$19.4K	﹤0.01%	324

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

ECM

Endurant Capital Management San Mateo, California $17.4M AUM 7.38% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vectors Research Management's ADAP Position: Q3 2022 in Review

Vectors Research Management sold out of Adaptimmune Therapeutics (ADAP) in Q3 2022, closing a stake of 7,000 shares — an estimated $12K sold.

Vectors Research Management first reported a position in ADAP in Q2 2021 and held it in 4 quarters. The position peaked at $31K in Q3 2021. 68 funds tracked by Wall St. Rank hold ADAP as of Q3 2022.

Vectors Research Management reported no remaining Adaptimmune Therapeutics position as of Q3 2022 after selling out during the quarter.
Vectors Research Management sold 7,000 Adaptimmune Therapeutics shares in Q3 2022, an estimated $12K.
Vectors Research Management first reported a position in Adaptimmune Therapeutics in Q2 2021 and held it in 4 quarters.
Vectors Research Management's Adaptimmune Therapeutics position peaked at $31K in Q3 2021.
68 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q3 2022.

Based on Vectors Research Management's 13F filing for Q3 2022, filed 8 Nov 2022.